Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9782727 | 0.91 | CYP19A1 (0.72) | CYP19A1SHBG | |
| SCHEMBL9782731 | 0.91 | CYP19A1 (0.72) | CYP19A1SHBG | |
| SCHEMBL28278507 | 0.89 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL7611386 | 0.88 | CYP19A1 (0.69) | CYP19A1SHBG | |
| SCHEMBL141797 | 0.87 | CYP19A1 (0.70) | CYP19A1 | |
| SCHEMBL194995 | 0.87 | CYP19A1 (0.70) | CYP19A1 | |
| SCHEMBL3663524 | 0.87 | CYP19A1 (0.64) | CYP19A1 | |
| SCHEMBL1651377 | 0.87 | CYP19A1 (0.64) | CYP19A1 | |
| SCHEMBL11562256 | 0.86 | CYP19A1 (0.74) | CYP19A1 | |
| SCHEMBL8375052 | 0.86 | CYP19A1 (0.63) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096087-A1 | TREATMENT OF MYELOID CELL DYSFUNCTION WITH MEMBRANE SPANNING 4-DOMAINS A6A (MS4A6A) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250134920-A1 | Treatment Of Myeloid Cell Dysfunction With Membrane Spanning 4-Domains A6A (MS4A6A) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20130281418-A1 | Use of hydroxypregnenolone derivatives for enhancing health and physical performance | MARCHEWITZ ERIC D (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130123175-A1 | Compounds for Delivery of Therapeutic And Imaging Moieties to Nerve Cells | HILL G CRAIG (US) | 2013-05-16 | — | — | US | disclosed |
| US-8232251-B2 | Compounds for delivery of therapeutic and imaging moieties to nerve cells | MANZANITA PHARMACEUTICALS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090286732-A1 | COMPOUNDS FOR DELIVERY OF THERAPEUTIC AND IMAGING MOIETIES TO NERVE CELLS | MANZANITA PHARMACEUTICALS, INC. | 2009-11-19 | — | — | US | disclosed |
| EP-1781268-A1 | TREATMENT OF MYOCARDIAL INFARCTION WITH 11HSD1 INHIBITORS | THE UNIVERSITY OF EDINBURGH (GB) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021744-A1 | TREATMENT OF MYOCARDIAL INFARCTION WITH 11HSD1 INHIBITORS | THE UNIVERSITY OF EDINBURGH (GB) | 2006-03-02 | — | — | WO | disclosed |
| US-20040120891-A1 | Compounds for intracellular delivery of therapeutic moieties to nerve cells | ASILOMAR PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| EP-0141684-B1 | HYDROCORTISONE-17-CARBOXYLIC-ACID ESTER 21-THIOCARBOXYLYC-ACID ESTERS, THEIR PREPARATION AND THEIR USE AS MEDICINES | JOUVEINAL S.A. (FR) | 1987-09-30 | — | — | EP | disclosed |
| EP-0141684-A1 | Hydrocortisone-17-carboxylic-acid ester 21-thiocarboxylyc-acid esters, their preparation and their use as medicines | JOUVEINAL S.A. (FR) | 1985-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040120891-A1 | Compounds for intracellular delivery of therapeutic moieties to nerve cells | CLTB, NMBR, OPRL1 | CYP19A1 4819/4885SHBG 2686/4885 |
| US-20090286732-A1 | COMPOUNDS FOR DELIVERY OF THERAPEUTIC AND IMAGING MOIETIES TO NERVE CELLS | CLTB, NMBR, L1CAM | CYP19A1 4413/4885SHBG 1513/4885 |
| US-20130123175-A1 | Compounds for Delivery of Therapeutic And Imaging Moieties to Nerve Cells | CLTB, NMBR, L1CAM | CYP19A1 4413/4885SHBG 1513/4885 |
| US-20130281418-A1 | Use of hydroxypregnenolone derivatives for enhancing health and physical performance | HSD17B11, CYP19A1, HSD17B1 | CYP19A1 2/4885SHBG 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.